Writing

A widow's suit over claims never reprocessed after reinstatement shows how leave policy, plan terms, and claims follow-up have to line up.

A federal court held a TPA plausibly acted as an ERISA fiduciary, and confirmed the employer is a fiduciary for selecting and monitoring it.

New Jersey's employer Medicaid fee faces a federal challenge where the tax question may matter more than ERISA preemption.

A Tennessee ERISA tobacco surcharge case shows that lawyers stay responsible for every citation an AI tool produces.

EBSA's enforcement priorities reach mid-sized plans, which need a right-sized fiduciary calendar of their own.

EBSA and the federal courts are both rewarding documented fiduciary decisions over outcomes.

The Glenn rule's lesson applies to benefits advisors: a recommendation should read as a neutral process from the file alone.

Under the Glenn rule, an ERISA conflict of interest isn't disqualifying, and a strong process record can keep it from deciding the case.

EBSA's FAB 2026-01 points health plans toward the committee process retirement plans have used for twenty years.

Benefits chatbots that misstate plan terms could create ERISA estoppel exposure, and buried disclaimers may not help.

Barbich v. Northwestern lets an ERISA claim over health plan options proceed, so medical menus deserve the same scrutiny as 401(k) lineups.

FAB 2026-01 shows EBSA will credit plan sponsors that can explain how vendor conflicts were evaluated and managed.

Fully insured plans are subject to ERISA, and confusing plan regulation with insurance regulation leads to expensive surprises.

Horizon BCBSNJ agreed to pay $100 million to settle False Claims Act allegations, a reason for every plan sponsor to verify its own payments.

In re MultiPlan raises the question of whether public price data could enable price compression and antitrust risk.

Shell companies with phantom employees used self-funded ERISA plans to evade state regulation, testing the framework's limits.

The District of Minnesota dismissed Navarro v. Wells Fargo, which is a reason for plan sponsors to strengthen process, not relax.

Lewandowski's amended complaint adds a plaintiff and COBRA-based relief that should support standing.

A welfare plan fiduciary committee provides oversight and documentation that mitigates growing ERISA litigation risk.

ERISA fiduciaries are held to high standards of loyalty and prudence, and those duties apply to welfare plans too.

Anyone exercising discretion over a health and welfare plan or its assets is an ERISA fiduciary.

Lewandowski's COBRA status means overpaid claims would raise her required contributions, so redressability wasn't speculative.

Navarro v. Wells Fargo shouldn't fall on Lewandowski's redressability grounds because Wells Fargo conceded the point.

Employee contributions become plan assets quickly, and mishandling them can lead to criminal charges.

Two of Lewandowski's claims against J&J were dismissed for lack of redressability, but more plaintiffs will test the law.

A $32,000 LTD calculation mistake shows why plan documents and SPDs should exist before anyone asks for them.

ERIC sued to overturn parts of the 2024 MHPAEA rule, setting up a fight over simplicity versus access.

Bass Pro Shops proposed a settlement in its ERISA tobacco surcharge class action, a signal for similar wellness suits.

Nearly every stakeholder in healthcare is suing another, and the litigation shows how widely costs are being inflated.

The Gurwitch lawsuit asks whether copay maximizers abuse patient protections, another item fiduciaries should evaluate.

Lewandowski's suit against J&J has already shifted how employers view their fiduciary role over health plans.

A tobacco surcharge suit argues former smokers deserve refunds for the waiting period, a theory without the usual standing flaw.

Kraft Heinz v. Aetna and similar suits are shifting power toward plan sponsors who use transparency data.

Paragraph 157 of Lewandowski's complaint shows why employers must look under the hood of their vendors.

ERISA preemption gives multistate employers one set of rules instead of fifty.

A suit against UnitedHealth over emergency payments raises the question of what a reasonable billed amount is.

Anti-assignment clauses in plan documents can defeat provider standing in ERISA litigation.

"Transparency" in PBM contracting means whatever the party defining it wants, so plan sponsors should test contract terms directly.

The Sixth Circuit found parts of Tennessee's PBM law preempted for self-funded plans, but it still applies to insured plans.

The FTC settlement requires Express Scripts to offer a standard contract, giving plan sponsors a benchmark for other PBMs.

A Tennessee audit found CVS Caremark paid its affiliated pharmacies more than others for the same drugs.

The FTC's PBM case shows antitrust enforcement is an underused healthcare reform tool, as Express Scripts settles and Caremark fights.

PBM antitrust cases affect employers directly through higher renewals.

A February 2026 federal law changes PBM contracting, so plan sponsors should ask about rebates, spread, and audit rights now.

Price is where the most money leaves a health plan, and new law requires PBMs to show plan sponsors the receipts.

GLP-1 drug trend of 11.7% reflects overcharging, because the drugs are inexpensive to make and distribute.

Martin Shkreli was a symptom of drug pricing incentives, and FTC data shows similar markups at PBM-affiliated pharmacies.

GLP-1 manufacturers lowered net prices, but plans still pay far above what a manufacturer will sell for directly.

The CAA extended 408(b)(2) fee disclosure to health plans, and failing to review vendor compensation can be a fiduciary breach.

Drug rebates trade dollars for quarters: they return only part of what the plan and its sickest members overpaid.

Gross-to-net is the gap between list and net drug prices, and patients rarely see those discounts.

An HHS analysis of two years of RxDC data shows how rebates affect drug spending and premiums.

GLP-1 list prices hold steady while net prices fall, and the difference flows through the rebate system.

An example from the FTC's PBM suit shows drug rebates hurt patients in HDHPs and those paying cash.

AWP, WAC, and other drug pricing terms obscure what a drug costs, and knowing them helps in PBM negotiations.

Spread pricing is a markup that raises P in E=CUP, and plan sponsors can contract for transparency.

Vertical integration raises healthcare expense when it increases prices without reducing utilization or caseload.

Express Scripts sued the FTC for defamation over its PBM report, part of fast-moving PBM scrutiny.

The same GLP-1 sells at very different prices to different buyers, while costing a few dollars to make.

Pharma CEOs blamed PBMs at a Senate hearing, but both sides share responsibility for high drug prices.

Rebates slowed Humira biosimilar adoption in the U.S., while Europe's lower-price model moved faster.

Good-faith legal analysis of a benefits program built on public federal law shouldn't require an NDA to read.

A double-dip reimbursement arrangement on the books is a purchase price and diligence problem for buyers and sellers, not only a tax issue.

Brokers can decline to place double-dip programs and report promoters to the IRS, which protects far more employers than one client.

A vendor letter that cites no opposing authority on a double-dip program is a reason to walk away from that vendor.

Double-dip wellness tax schemes keep resurfacing under new names, and brokers need tools to recognize and push back on them.

A double-dip promoter's refusal to share plan documents is telling, because a §105(b) analysis rests entirely on public law.

Under §105(b) there must be a real medical expense to reimburse, and wellness double-dip schemes reimburse something else.

Wellness tax savings plans always cost about $1,200 a month because of structural features that fail the same regulatory test.

A wellness program promising six figures in FICA savings is a long-running scam, and the employer is left holding the liability.

No tax code provision lets employers and employees erase payroll taxes through a wellness plan.

A New Jersey out-of-network arbitration award at 36 times the carrier's offer should prompt self-funded plans that opted in to recheck that decision.

FAIR Health data suggests the No Surprises Act may shift care in-network and pressure reference-based pricing.

NABIP's model Rx transparency language became Virginia law in 2025, and the same member-driven approach can work in other states.

NABIP's Employer Working Group drafted a second model bill giving employers a right to their own claims data within 30 days.

The CREDIT Act is NABIP model legislation built on what Texas and Tennessee already do well on employer claims data.

Repealing the employer health insurance tax exclusion raises taxes on workers without touching the cost of care that drives premiums.

H.R. 7895 targets PBM payments to brokers, the smallest dollars in the chain, while vertical integration goes untouched.

NABIP's Employer Working Group legislation has begun its path in New Jersey with lobbyist support.

Rebate pass-through laws take 30 months to take effect, so plan sponsors can't wait for Congress to protect their dollars.

A proposed FY26 budget bill takes aim at Rx rebates and PBM practices, a step forward that leaves other revenue streams untouched.

NABIP's Lower Rx Cost Working Group drafted the association's first model legislation, and part of it became Virginia law.

MedPAC misjudges Medicare brokers, who advocate for beneficiaries even when carriers cut commissions.

The Senate HELP Committee made bipartisan PBM reform a 2025 priority.

Language from NABIP's Lower Rx Costs working group was introduced as legislation in Virginia.

Two NABIP-backed bills easing ACA reporting and disclosure requirements were signed into law.

The December 2024 CR averted a shutdown but dropped bipartisan PBM reform, which advocates would push again.

PBM reform came close in the December 2024 CR before being pulled, and reform still depends on people showing up.

The December 2024 continuing resolution draft included real PBM reform for employer plans.

Two Senate health finance bills previewed possible changes for individuals and small groups.

Making COBRA creditable coverage for Medicare enrollment would help seniors and taxpayers.

I testified before the NJ Senate Commerce Committee for a bill aligning state MLR calculations with the federal method.

Congress punted on bipartisan health cost reforms that polls show have near-universal support.

Medicare beneficiaries need broker and FMO expertise, and policy changes that reduce it harm them.

The Lower Costs, More Transparency Act (H.R. 5378) would bring PBM and price transparency reforms.

Using AI to weigh sick days or medical leave in layoff decisions creates legal exposure that needs the same review a lawyer would give a memo.

Health plans still follow a 2002 electronic disclosure safe harbor, and EBSA's proposed update needs practitioner comments.

The two leading Medicare certifications both satisfy CMS, but only one supports an organization that advocates for agents.

The IRS quietly updated Form 720 for the PCORI fee, so filers should confirm Line 133 shows the right dates and amounts.

HIPAA lets a benefits steering committee use PHI for plan operations, but never for employment decisions, and a written policy should say so.

Every carrier owes a Schedule A for insured benefits on the Form 5500, and missing ones are why filings go late.

Self-funded and level-funded plans owe the PCORI fee on IRS Form 720, and it is frequently missed because payroll never hears about it.

PCORI fees and the Form 5500 both come due July 31 for calendar-year plans, so assign owners and confirm vendor data early.

A federal employee's ineligible dependents cost his plan over $100,000, showing why dependent eligibility audits are a fiduciary task.

MHPAEA NQTL compliance breaks down when plan sponsors can't explain how named factors apply to their own plan.

CMS found that none of the MHPAEA comparative analyses it reviewed over two years were sufficient on first submission.

Dependent audits aren't the only lever on plan caseload, and spousal HRAs and opt-out incentives are within reach.

A court question about whether one employee triggers state insurance law could reshape regulation of fully insured plans.

CMS proposed a fix to the simplified creditable coverage determination for Part D, with comments due February 10, 2025.

CMS offered relief for plan sponsors that can't get vendors to remove every gag clause, rewarding good-faith effort.

There are six ACA 1094 and 1095 forms, each with a different purpose for employers and individuals.

Electronic SPD disclosure saves money, but only when it follows ERISA's requirements for access and participant rights.

The 2024 MHPAEA rule required plan sponsors to select a comparative analysis vendor and document the selection.

The CR failure ended the HDHP telehealth safe harbor for 2025, so plans needed to review their telehealth design.

Plan sponsors needed to act on the HIPAA reproductive health PHI final rule before its December 23, 2024 effective date.

MHPAEA comparative analysis duties for 2025 belonged on every health and welfare fiduciary's list.

HIPAA gives individuals a right to their medical records within 30 days, and denials should be challenged.

HIPAA's treatment, payment, and operations exception often lets plan sponsors access claims data they're told they can't have.

MLR rebates and level-funded surpluses may be plan assets, and plan sponsors must handle them under ERISA rules.

2025 Part D changes affect creditable coverage for employer groups with Medicare-eligible members.

ACA employer reporting requirements are overly complex and should be simplified.

ARPA offered eligible people who lost coverage a 100% COBRA premium subsidy.

DOJ's fast OhioHealth settlement targets contract terms that also sit in carrier agreements nationwide, a clear example of consolidation harm.

Hospital facility fees hide on the claim, and NABIP is backing H.R. 8684 to make them visible.

Price transparency alone hasn't changed patient behavior, and NABIP's model language adds Rx to make shopping worthwhile.

A health plan renewal is a compensation decision, because premium increases hit lower-paid workers hardest.

Hospital mergers drive medical trend, so provider market structure belongs in the renewal conversation.

The best utilization management feels like a benefit to members, not added pain through prior auth and step therapy.

Hospital price transparency was always the law, and enforcement is now catching up with six-figure penalties.

Caseload is the E=CUP variable employers try least to move, though there are levers that don't harm employee trust.

E=CUP works as a framework for deciding which questions to ask about health plan costs.

Prior authorization manages who gives up on care, and smarter routing beats fewer approvals.

Healthcare financing follows an equation, and every renewal can be broken down by caseload, utilization, and price.

Renewal explanations change every year, but E=CUP shows plan sponsors which variable actually moved.

Chrysler's 1984 healthcare cost problem is still today's problem, and employers who ask why are in a stronger position.

Your healthcare costs are someone else's revenue, and if you don't manage them, someone will manage you.

New Jersey individual market rates for 2026 rose an average of 15.9%, with enhanced subsidies a key variable.

A $5,000 U.S. CT scan charge for a service costing about $1,000 in cash shows how negotiated rates can exceed cash prices.

Brokers may value ICHRA as a tool for client fit and recruiting, even though individual commissions are lower.

Only three states increased small-employer coverage rates between 2002 and 2023, which calls for rethinking coverage mandates.

ICHRA is a strong fit for some employers and a poor fit for others, depending on individual factors.

Employers consider ICHRA when group coverage isn't viable or when they want defined contributions and choice.

An SFO airport surcharge for employee health benefits makes visible the hidden healthcare tax in everything we buy.

Carriers want ICHRA for large groups because individual business can be more profitable than group.

Major carriers are investing in ICHRA, but it needs to work for employers and individuals to become a destination rather than a last resort.

A doctor treated a patient for cancer they never had for eleven years, a reminder that fraud in care harms patients directly.

BLS data shows small-employer premiums and contributions up and participation down, raising questions about subsidy integrity.

When deductibles reset, cash-price and pharmacy tools can help people compare costs against their plan's negotiated rates.

Maryland's all-payer rate setting has curbed hospital spending but doesn't address drug costs or physician fees.

Rising denials and prior authorization need reform that keeps care patient-centered while controlling cost.

Low-value care charges full price for services that do little for patients, according to HCCI data.

Healthcare inflation has outpaced everything else since 1992, and the drug supply chain still needs price transparency.

A Peterson-KFF analysis asks whether lower drug prices abroad come from negotiation, competition, or both.

Two Denver urgent care bills for the same visit show why insurers' confidential pricing undermines transparency law.

The employer tax exclusion began with a WWII wage freeze, and repealing it would raise coverage costs for workers.

Upcoding inflates medical bills, and False Claims Act enforcement is one way to fight it.

Small-group fully insured plans face a death spiral as healthier groups leave for self-funding.

Horizontal integration raises prices without changing utilization or caseload, so employers pay more for nothing extra.

The medical loss ratio rewards higher prices, a well-intended policy that should be eliminated.

E=CUP (expense equals caseload times utilization times price) is the equation behind healthcare costs at every scale.

A review found widespread hospital noncompliance with price transparency rules, raising the question of stronger CMS enforcement.

A GAO report found fewer insurer competitors since the ACA, contrary to its competition goals.

EBRI found HDHPs don't change overall plan spending and can reduce needed care.

New Jersey's State Health Benefits Plan spending is outpacing even rising premiums.

Turquoise Health data on nearly 400,000 negotiated rates shows price transparency is producing usable comparisons.

32BJ's Healthcare Administrative Report is a model of the prudent-expert work fiduciaries should practice.

KFF's 2024 survey shows family coverage costs as much as an economy car, absorbing workers' wage growth.

Provider network fights work like TV carriage disputes, and plan sponsors end up paying the higher price.

New Jersey spent $550,000 to cancel $100 million in medical debt for nearly 50,000 residents.

Pharma's direct-to-consumer marketing spend exceeds Medicare negotiation savings, undercutting the R&D argument.

Medicare's first drug price negotiations were projected to save $6 billion, raising broader economic questions.

A $2.75 billion fraud case shows why eliminating prior authorization would increase fraud, overuse, and waste.

Provider consolidation raises prices and harms communities, as network contract fights show.

The U.S. spends more of its GDP on medical care, but not on medical care plus social services combined.

The 2024 Milliman Medical Index puts the cost of employer coverage at $32,066 for a family of four.

Hospital financial data shows hospitals are profitable on Medicare, despite the industry's annual underpayment claims.

32BJ's attempt to exclude NewYork-Presbyterian shows how hospital contract terms can control an employer plan's network.

The RAND hospital price study shows employer-sponsored plans pay the inflated prices, not cash-paying patients.

Hospital claims about administrative costs ignore what private equity ownership and executive pay take out of premiums.

HFMA's resistance to price transparency puts it on the wrong side of the issue.

A KFF poll found 74% of Americans fear unexpected medical bills, more than food or rent costs.

A $2 billion fraud case shows why plans can't approve everything providers request.

A Peterson-KFF study shows medical debt is widespread and unevenly distributed across the U.S.

Site-neutral payment reform would stop paying hospital outpatient departments more for the same service.

A Lown Institute study questions whether nonprofit hospitals provide enough community benefit to justify their tax breaks.

Americans pay far more than other countries for identical drugs, and the R&D argument doesn't justify it.

The proposed Atlantic Health and Saint Peter's merger would reshape a New Jersey hospital market employers rely on.

Family coverage is no longer affordable for many of the nearly 50 million people working for smaller companies.

With only 1.1% of physicians opting out of Medicare, its rates appear sufficient to cover the cost of care.

The Twin City Fire v. SHRM coverage fight is a reminder to match the services you provide to what your E&O policy actually covers.

AI helps experienced operators do more, but the hard problems in benefits still require expertise, not prompt engineering.

The Howden, Hays, and Brown & Brown dispute raises the question of whether lawful growth tactics are ethical for brokers.

Two brokers posting nearly identical case studies is a reminder that authenticity matters in marketing.

Buyers of point solutions need to distinguish innovators from imitators and impostors before signing.

Treat AI-generated compliance answers as suspect until you verify the cited law yourself.